shRNA-mediated

silencing of MSH2 resulted in shorter repeat lengths suggesting that FRDA iPS cells could be a useful system to evaluate the mechanisms of repeat expansions and contractions in disease. It remains to be shown whether FRDA iPS cells will demonstrate cell-type-specific expansions of GAA repeats. GAA repeat mutations are unstable and progressive and postnatal instability occurs in various tissues throughout life. For example, large GAA repeat expansions are especially prominent in the dorsal root ganglia of FRDA patients, this website which harbor cell bodies of sensory neurons, a neuronal subtype especially affected in FRDA (De Biase et al., 2007). Given FRDA-iPS cells can be directed to differentiate into sensory neurons, as well as cardiomyocytes, the presence Temozolomide clinical trial and mechanisms of tissue-specific expansion should be testable (Liu et al., 2010). Disease modeling using human pluripotent stem cells might greatly benefit if the genome

of these cells could be readily modified. For instance, the generation of transgenic “reporter” cell lines using fluorescent reporter genes under the control of cell-type-specific promoters could enable the purification, tracking, and functional characterization of disease relevant cells after directed differentiation. It is our experience that use of such reporter genes is a significant consideration. Most in vitro differentiation strategies result in a heterogenous population of differentiated cells, which can include progenitors and a variety of cellular intermediates. Therefore, having the ability to prospectively identify, purify, and easily track the desired cell type by means of reporter-gene

expression can facilitate downstream disease-specific assays, which could be hindered by the presence of other cell types. The availability of stem cell lines harboring cell-type-specific reporters could also aid in the improvement of procotols for the directed differentiation of disease relevant cell types for nearly which efficient differentiation techniques are not yet available. In addition, the ability to overexpress or downregulate a particular gene of interest could be used in the future to recapitulate or rescue a disease-relevant phenotype. For instance, loss-of-function monogenic disorders could be mimicked using a wild-type cell line by downregulation of the particular disease-associated locus. Conversely, a loss-of-function disease-specific phenotype could be rescued by overexpression of the wild-type form of the gene. Finally, the use of gene-targeting strategies to correct or induce a particular genetic defect will allow for the generation of isogenic lines with and without a disease genotype.